<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01709318</url>
  </required_header>
  <id_info>
    <org_study_id>P06109</org_study_id>
    <secondary_id>2012-002459-41</secondary_id>
    <nct_id>NCT01709318</nct_id>
  </id_info>
  <brief_title>A Dose-Finding Study to Evaluate Ovarian Function and Vaginal Bleeding in Next Generation Rings (P06109/MK-8175A/MK-8342B-012)</brief_title>
  <official_title>A Multicenter, Randomized, Partially-blinded, Phase IIb Dose-finding Study on Ovarian Function, Vaginal Bleeding Pattern, and Pharmacokinetics Associated With the Use of Combined Vaginal Rings Releasing 17β-estradiol Plus Three Different Doses of Either Nomegestrol Acetate or Etonogestrel in Healthy Women Aged 18-35 Years. Protocol MK-8175A/MK-8342B 012</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to the evaluate ovulation inhibition, vaginal bleeding, and
      pharmacokinetics associated with three different doses of two next generation vaginal rings
      (NGRs), identifying at least one whose control of menstrual cycles is not inferior to that of
      NuvaRing®.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Progesterone Concentrations &gt;16 nmol/L</measure>
    <time_frame>Day 1 of Treatment Cycle 1 through Day 28 of Treatment Cycle 3 (Study Days 1-84)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Break-through Bleeding and/Or Spotting (BTB-S) During Cycle 3</measure>
    <time_frame>Day 1 of Cycle 3 through Day 28 of Cycle 3 (Study Days 57-84)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Withdrawal Bleeding-spotting During Cycle 2</measure>
    <time_frame>Day 1 of Cycle 2 through Day 28 of Cycle 2 (Study Days 29-56)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of Withdrawal Bleeding During Cycle 2 (Defined as the Ratio of Number of Withdrawal Bleeding Days/Number of Withdrawal Bleeding And/Or Spotting Days)</measure>
    <time_frame>Day 1 of Cycle 2 through Day 28 of Cycle 2 (Study Days 29-57)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of BTB-S during Cycle 3 (Defined as the Ratio of the Number of Breakthrough Bleeding Days/Number of BTB-S days)</measure>
    <time_frame>Day 1 of Cycle 3 through Day 28 of Cycle 3 (Study Days 57-84)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Venous or Arterial Thrombotic/Thrombolic Events</measure>
    <time_frame>From Cycle 1, Day 1 up to 8 days after Day 28 of Cycle 3 (Study Days 1 through 91)</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">666</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>NOMAC-E2 500/300</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive NOMAC-E2 500/300 for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NOMAC-E2 700/300</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive NOMAC-E2 700/300 for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NOMAC-E2 900/300</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive NOMAC-E2 900/300 for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ENG-E2 75/300</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ENG-E2 75/300 for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ENG-E2 100/300</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ENG-E2 100/300 for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ENG-E2 125/300</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ENG-E2 125/300 for three 28-day treatment periods, each treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NuvaRing® (ENG-EE 120/15)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive NuvaRing® for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nomegestrol acetate (NOMAC)</intervention_name>
    <description>Daily release of 500, 700, or 900 μg.</description>
    <arm_group_label>NOMAC-E2 500/300</arm_group_label>
    <arm_group_label>NOMAC-E2 700/300</arm_group_label>
    <arm_group_label>NOMAC-E2 900/300</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etonogestrel (ENG)</intervention_name>
    <description>Daily release of 75, 100, or 125 μg</description>
    <arm_group_label>ENG-E2 75/300</arm_group_label>
    <arm_group_label>ENG-E2 100/300</arm_group_label>
    <arm_group_label>ENG-E2 125/300</arm_group_label>
    <arm_group_label>NuvaRing® (ENG-EE 120/15)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethinyl estradiol (EE)</intervention_name>
    <description>Daily release of 15 μg</description>
    <arm_group_label>NuvaRing® (ENG-EE 120/15)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol (E2)</intervention_name>
    <description>Daily release of 300 μg</description>
    <arm_group_label>NOMAC-E2 500/300</arm_group_label>
    <arm_group_label>NOMAC-E2 700/300</arm_group_label>
    <arm_group_label>NOMAC-E2 900/300</arm_group_label>
    <arm_group_label>ENG-E2 75/300</arm_group_label>
    <arm_group_label>ENG-E2 100/300</arm_group_label>
    <arm_group_label>ENG-E2 125/300</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) ≥18 and ≤35

          -  Regular cycles from 24 to 35 days in length, with an intraindividual

        variation of ±3 days permitted within this range

          -  Good physical and mental health

        Exclusion Criteria:

          -  Diabetes mellitus with vascular involvement

          -  Presence of a severe or multiple risk factor(s) for venous or arterial

        thrombosis

          -  Severe dyslipoproteinemia

          -  Severe hypertension

          -  Presence or history of pancreatitis associated with severe

        hypertriglyceridaemia

          -  Presence or history of severe hepatic disease

          -  Undiagnosed vaginal bleeding

          -  Known or suspected pregnancy

          -  Participation in another investigational drug study within 30 days prior to

        screening visit

          -  History of malignancy ≤5 years, except for adequately treated basal cell or

        squamous cell skin cancer, or in situ cervical cancer

          -  Documented abnormal cervical smear result in 6 months prior to screening

        visit

          -  Sterilization using using a fallopian tube occlusion device (e.g., Essure

        method)

          -  Sex hormone therapy within 2 months prior to screening visit for purpose

        other than contraception, or injectable hormonal contraception within 6

        months prior to screening
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Spain</country>
  </removed_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2012</study_first_submitted>
  <study_first_submitted_qc>October 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2012</study_first_posted>
  <last_update_submitted>September 23, 2015</last_update_submitted>
  <last_update_submitted_qc>September 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Etonogestrel</mesh_term>
    <mesh_term>Megestrol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

